FDA Aligns on 12-Patient Pivotal Phase 2 Design for RP-A501 in Danon Disease

summarizeSummary

Rocket Pharmaceuticals announced FDA alignment on the pivotal Phase 2 trial design for RP-A501 in Danon disease, including a 12-patient efficacy population, recalibrated dose, and 12-month co-primary endpoints intended to support accelerated approval.

check_boxKey Events · Product Development and Regulatory · RCKT

• FDA Aligns on Pivotal Phase 2 Design

  FDA confirmed the pivotal efficacy population of 12 male patients treated with RP-A501 at the recalibrated dose of 3.8 × 10¹³ GC/kg using commercial-grade product.

• First Three Patients Count Toward Pivotal Population

  The first three patients treated under the modified protocol count toward the 12-patient pivotal population, leaving nine additional patients to be enrolled and treated.

• Co-Primary Endpoints Confirmed for Accelerated Approval

  FDA confirmed the established 12-month co-primary endpoints of myocardial LAMP2 protein expression and a 10% reduction from baseline in left ventricular mass index, intended to support a potential accelerated approval pathway.

• Dosing Completion Expected by Mid-2027

  Rocket expects to complete dosing of the remaining nine patients by mid-2027, with the primary assessment occurring at 12 months post-treatment.

auto_awesomeAnalysis · RCKT · Life Sciences

The FDA has formally aligned with Rocket on the pivotal Phase 2 trial design for RP-A501 in Danon disease, confirming the 12-patient efficacy population, the recalibrated dose of 3.8 × 10¹³ GC/kg, and the 12-month co-primary endpoints intended to support accelerated approval. The first three patients treated under the modified protocol count toward the pivotal population, leaving nine additional patients to enroll, with dosing completion expected by mid-2027. This removes a major regulatory uncertainty for the lead program and provides a clear path to a potential accelerated approval filing.